FDA gives priority review to Spectrum blood-cancer drug

|About: Spectrum Pharmaceuticals,... (SPPI)|By:, SA News Editor

The FDA has given a priority review designation to Spectrum Pharmaceuticals' (SPPI +3.5%) filing of a New Drug Application (NDA) for its Beleodaq blood-cancer treatment .

The FDA has set a deadline of August 9 for deciding whether or not to authorize Beleodaq.

Spectrum has requested that the FDA approve Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. (PR)